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Neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure is an increasing problem.
Variability in assessment and treatment of NAS has been attributed to the lack of high-quality evidence to guide
management of exposed neonates. This systematic review examines available evidence for NAS assessment tools,
nonpharmacologic interventions, and pharmacologic management of opioid-exposed infants. There is limited data
on the inter-observer reliability of NAS assessment tools due to lack of a standardized approach. In addition, most
scales were developed prior to the prevalent use of prescribed prenatal concomitant medications, which can
complicate NAS assessment. Nonpharmacologic interventions, particularly breastfeeding, may decrease NAS severity.
Opioid medications such as morphine or methadone are recommended as first-line therapy, with phenobarbital
or clonidine as second-line adjunctive therapy. Further research is needed to determine best practices for
assessment, nonpharmacologic intervention, and pharmacologic management of infants with NAS in order to
improve outcomes.
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Between 2000 and 2009, antepartum opioid use in-
creased from 1.19 to 5.63 per 1000 live births in the
United States. Concurrently, the incidence of neonatal
abstinence syndrome (NAS) increased from 1.20 to 3.39
per 1000 live births, and related hospitalization costs in-
creased from $39,400 to $53,400 per infant with NAS
[1]. NAS is characterized by gastrointestinal, respiratory,
autonomic, and central nervous system disturbances
from opioid withdrawal that affect critical regulatory
areas of postnatal life adaptation [2]. Fifty to eighty per-
cent of opioid-exposed infants require pharmacologic
treatment for NAS [3-5]. Recently, studies have suggested
that in-utero exposure to nicotine, selective serotonin re-
uptake inhibitors, and benzodiazepines may influence
NAS [6,7]. A better understanding of the effects of mater-
nal opioid–agonist medications, breastfeeding, genetic fac-
tors, and polypharmacy on the severity of withdrawal and* Correspondence: Sarah.Bagley@bmc.org
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unless otherwise stated.the need for pharmacotherapy will help to optimize as-
sessment and management [3,6,8,9].
Despite this growing problem, great variability persists
in the assessment and management of opioid-exposed
infants, with only half of neonatal intensive care units
(NICUs) with accredited fellowships having a protocol
for NAS management [10]. In addition, no medications
are currently approved by the FDA for use in NAS man-
agement or prenatal opioid dependence. Buprenorphine
and methadone are currently labeled as FDA Category
C: “Animal reproduction studies have shown an adverse
effect on the fetus and there are no adequate and well-
controlled studies in humans, but potential benefits may
warrant use of the drug in pregnant women despite po-
tential risks.” It is important to recognize that although
these drugs may not be FDA approved for use in preg-
nancy, the risks associated with continued use of illicit
drugs or misuse of prescription medications is far
greater. In addition to the benefits of methadone or
buprenorphine to treat withdrawal symptoms and re-
duce cravings, pregnant women in treatment may have
access to other treatment such as counseling, infection
screening, and fetal growth monitoring, which can leadLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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There are decades of experience with methadone use in
pregnancy, and it has long been considered the gold
standard in treating pregnant women with opioid depend-
ence. Methadone has been shown to decrease intrauterine
growth restriction, prematurity, and fetal distress com-
pared to heroin use only [11-14]. Recently, the World
Health Organization included a recommendation for
women with opioid dependence to be maintained on ei-
ther methadone or buprenorphine during pregnancy
[15]. While some studies suggest that prenatal bupre-
norphine decreases NAS severity compared to metha-
done, the interpretation of these comparative studies is
limited by important differences in women treated with
buprenorphine versus methadone, such as bias from
study dropout and confounding by indication [3,16-21].
Nonetheless, it is important that women have access to
two effective treatment options and that both have rea-
sonable safety profiles for the exposed fetus.
Given this variability in clinical practice, several clin-
ical narrative reviews have been written to guide practice
for NAS management, focusing primarily on pharmaco-
logic treatment regimens [4,5,22,23]. Those reviews have
commented on the lack of randomized trials or solid evi-
dence guiding current assessment and management of
NAS. The objective of this review is to summarize avail-
able evidence on the assessment and management of in-
fants exposed to opioids in utero, including assessment
tools used for NAS scoring, nonpharmacologic interven-
tions, and pharmacologic management of NAS.
Methods
We conducted a systematic search of the published
English-language literature of studies on 1) assessment of
NAS, 2) nonpharmacologic interventions for NAS, and 3)
pharmacologic treatment of NAS. To identify articles, two
of the authors (SMB and EH) searched PubMed and the
Cochrane Database and searched the references in identi-
fied articles. Articles published between 1975 and Novem-
ber 15, 2013, are included in the results.
For assessment articles, the search terms included were:
neonatal abstinence syndrome assessment, neonatal abstin-
ence score, neonatal drug withdrawal score, neonatal drug
withdrawal assessment, Finnegan score, Lipsitz score, and
modified Finnegan score. For the nonpharmacologic inter-
vention articles, we used the search terms: neonatal ab-
stinence syndrome nonpharmacologic treatment, neonatal
abstinence syndrome management, and neonatal abstin-
ence syndrome treatment. For pharmacologic manage-
ment, the search terms were: neonatal abstinence syndrome
pharmacologic treatment, neonatal abstinence syndrome
management, and neonatal abstinence syndrome treatment.
Different inclusion criteria were applied for the three
study categories due to varying availability of data andtypes of studies conducted in each area. We included
studies of assessment tools developed for the clinical
diagnosis and management of NAS. For nonpharmacolo-
gic treatment, we included studies composed of cohort,
case series, case–control, and randomized controlled tri-
als (RCTs). For pharmacologic treatment, only RCTs and
nonrandomized experimental studies were included. For
nonpharmacologic intervention and pharmacologic treat-
ment studies, articles were only included if they defined
objective NAS outcome measures. We excluded studies
that examined the use of paregoric as pharmacologic
treatment because although it was commonly used in
NAS treatment in the past, it is no longer recommended
due to issues with impurity [4,24]. NAS outcomes
measures extracted included inter-rater variability for
NAS scoring, length of pharmacologic treatment for




Of 368 articles identified through our search terms, eight
specifically pertained to the evaluation of assessment
tools for NAS. Of those eight articles, four are included
in this review. In addition, we have included the results
of the assessment tool used in the MOTHER (Maternal
Opioid Treatment: Human Experimental Research) study.
The four excluded studies were eliminated due to clin-
ical issues. For example, one excluded study used infant
sucking as the study outcome of NAS improvement;
however, routine use of this measurement tool is not
practical for most nurseries because it requires an in-
strument to measure sucking, which is not practical,
and whose use is uncommon [25]. A second excluded
study evaluated neurobehavioral assessment using the
NICU Network Neurobehavioral Scale, which was not
meant to be used in routine clinical care for the treat-
ment of withdrawal in infants with NAS [26]. A third
excluded study used an adjuvant tool whose use is not
intended to replace a full assessment tool [27]. The
fourth excluded study examined the use of an actigraph
(portable motion detector that measures movement),
which would not be practical for clinical use [28].
The assessment tools for NAS are provided in Table 1.
They were all developed in the United States. The first
was the Neonatal Abstinence Syndrome Score (NASS),
or what is commonly referred to as the Finnegan Score
(FS). This scale or a modified version is the most widely
used NAS scale in the US [3,5]. It had a high inter-rater
reliability coefficient of 0.82 when initially developed
[29,30]. The second tool developed was the Narcotic
Withdrawal Score, or the Lipsitz Score [31]. There was
no inter-rater reliability determined; only infants who
scored above a certain threshold had been exposed to
Table 1 Studies of tools to assess neonatal abstinence syndrome
Reference Index vs. reference group(s) Scale Primary results
Finnegan, 1975 [29] 37 infants assessed with NASS vs.






Exposure methadone and heroin 20 items, weighted on
pathologic severity
Management of NAS without
drug Rx: 30% vs. 46%
LOS: 6 days vs. 8 days
Total Rx days decreased by 25%
Lipsitz, 1975 [31] 41 infants evaluated by 2 pediatric
residents, placed in 5 groups, one
group which was opioid exposed
Narcotic Withdrawal Score Only the infants exposed to opioids
had scores≥ 5; concluded that a score
> 4 suggests a clinical threshold for Rx
Exposure methadone and heroin 11 items, scored 0–3 based on severity
Green, 1981 [32] Infants exposed to methadone
or heroin(n = 50)
Neonatal Narcotic Withdrawal Index Inter-rater reliability coefficient: 0.771*
Control infants (n = 40) 7 items, scored 0–2 based on severity Mean NAS score on day 2
of life: 1.57 vs. 3.08*
7th item is “other” and includes
12 other symptoms
Zahorodny, 1998 [33] Group A: opioid-exposed infants
with NAS (n = 30)
Neonatal Withdrawal Inventory Group A: inter-rater reliability
coefficient: 0.89–0.98
Group B: opioid infants with NAS (n = 12)
and nonopioid-exposed controls (n = 13)
8 items given predetermined weights Group B: sensitivity and specificity
for NAS diagnosis: 100%, 100%
Group C: opioid-exposed infants
with NAS (n = 25)
Group C: sensitivity and specificity for
Rx threshold vs. the NASS: 100%, 100%
Jones, 2010 [3] 131 opioid-exposed infants,
scored using the same scale
MOTHER NAS scale (modified Finnegan) Intraclass correlation coefficient > 0.94
Exposure methadone or buprenorphine
Abbreviations: NAS Neonatal Abstinence Syndrome, NASS Neonatal Abstinence Scoring System, Rx Treatment, LOS Length of Hospital Stay.
*indicated p < 0.05.
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threshold score for NAS treatment. The next scale devel-
oped is called the Neonatal Narcotic Withdrawal Index,
which has an inter-rater reliability coefficient of r = 0.771
(p < 0.01) [32]. The fourth scale we reviewed is the Neo-
natal Withdrawal Inventory (NWI). The NWI was able to
correctly identify withdrawing infants with a specificity
and sensitivity of 100 percent when Finnegan’s NASS was
used as the gold standard. The inter-rater reliability coeffi-
cient was 0.89–0.98 for the NWI, compared with 0.7–0.88
for Finnegan’s NASS [33]. The final scale is the MOTHER
NAS scale, which is a modified Finnegan scale. They esti-
mated an intraclass correlation coefficient for the degree
of agreement between an expert rater and a site rater (the
MOTHER trial was an international, multisite trial) and
found that the lowest coefficient exceeded 0.94 [3].
Nonpharmacologic interventions
Of the 879 articles we identified pertaining to nonpharma-
cologic interventions, 13 were included in this review.
Infant feeding method
The majority of evidence for the nonpharmacological man-
agement of NAS is in the area of infant feeding method.Breastfeeding is recommended in stable mothers on
methadone and buprenorphine maintenance therapy
who are not concurrently using illicit drugs. The defin-
ition of stable will vary by institution; for example, the
policy may state that in order to be eligible to breast-
feed, the mother will have had no positive urine toxicol-
ogy screens and been adherent with treatment in the
last trimester [11,22,34,35]. Transfer of methadone and
buprenorphine into breast milk is minimal and unre-
lated to maternal dose [8,36]. Breastfeeding has been
shown to act as an analgesic for infants and is estab-
lished as beneficial for soothing agitated infants [37].
Seven studies were identified that examined the role of
infant feeding method on NAS outcomes [9,38-43]. All
studies were retrospective cohorts of primarily full-term
infants exposed to methadone, heroin, and buprenorphine
and were determined to have NAS symptoms. Studies did
not consistently differentiate between expressed breast
milk and breastfeeding. Some studies did not compare ex-
clusive breastfeeding versus combination feeding and
those fed with formula only. Duration of breastfeeding
was also not defined by the majority of studies. Five of the
seven studies specified the NAS scoring assessment used,
but there was variation both in the threshold for initiating
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treatment used. Criteria for permitting breastfeeding were
not described in every study, which introduced bias that
was not addressed in these studies.
The primary findings of the seven studies are pre-
sented in Table 2, indicating an overall decreased need
for pharmacologic treatment, a decrease in NAS scores,
and decreased length of pharmacologic therapy and
hospitalization for infants who were breastfed primarily
or breastfed to any extent. In four of the studies, length
of hospitalization was 3–19 days shorter in breastfed in-
fants [9,38,41,43]. In four of the studies, infants who
were breastfed to any extent had up to 30 percent reduc-
tion in their need for pharmacologic treatment for NAS
[9,38,41,42]. In addition, one study found that predomin-
antly breastfed infants demonstrated signs of withdrawal
significantly later than formula-fed infants (10 vs. 3 days;
p < 0.001), with decreased Finnegan withdrawal scores in
the first 9 days of life [38].
Other nonpharmacologic interventions
Other nonpharmacologic interventions that have been
described include rooming-in, bed type, positioning of
the infant, and non-insertive acupuncture (NIA). The
primary findings are presented in Table 2. Two retro-
spective studies of rooming-in found overall decreased
length of hospital stay and duration of therapy [44,45].
Two studies examined the role of bed type on NAS out-
comes. In the first study, infants randomly assigned to a
rocking bed with accompanying intrauterine sounds had
higher mean withdrawal scores that were statistically
nonsignificant and an increase in sleep disturbance that
was only statistically nonsignificant on day 7 of life [46].
In the second study, in which infants were randomly
assigned to an experimental nonoscillating waterbed or a
regular crib, those in the waterbed required less pharma-
cologic treatment for NAS [47]. In another study on po-
sitioning, 48 infants were randomly assigned to either
supine or prone sleeping positions; those infants placed
in a supine position had significantly higher peak and
mean withdrawal scores and higher mean caloric intake
[48]. Finally, one study examined the role of NIA on
NAS as adjunctive therapy for infants receiving treat-
ment for NAS. Infants included in the study were diag-
nosed although their pharmacologic treatment was not
specified. After the NIA sessions, babies were subject-
ively noted to have improved sleep, with decreased rest-
lessness and improved feeding [49].
Pharmacologic management
Out of 940 published articles identified using our search
terms for pharmacologic treatment, seven studies met
our inclusion criteria. Of note, there are studies included
in the Cochrane Reviews that are not included in ourreview because they examined studies using paregoric or
unpublished data. The primary results of the seven se-
lected studies are presented in Table 3.
Two studies compared morphine with phenobarbitone
and with diluted tincture of opium (DTO), respectively.
In the first study, 75 infants were enrolled in a double-
blind RCT to compare morphine with phenobarbitone
in infants with two consecutive Lipsitz scores of > 4. Me-
dian treatment duration was significantly shorter in the
morphine group. Infants treated with phenobarbitone re-
quired more frequent second-line treatment with chloral
hydrate (47% vs. 35%; p = 0.11) and admission to a spe-
cialty care baby unit (62% vs. 30%; p = 0.04) [50]. The sec-
ond study compared randomized treatment of NAS with
tincture of opium versus morphine in 33 infants and used
the FS assessment for NAS treatment initiation and dis-
continuation. Both length of treatment and length of stay
were longer in the morphine group (29.8 vs. 26.9 days and
37.5 vs. 32.4 days; p > 0.05) [51].
Two studies examined the use of buprenorphine to
treat NAS. In both studies, a modified FS was used to
assess infants, and three consecutive scores of ≥ 24 was
the threshold for treatment. The first study enrolled 26
infants to a Phase I, randomized, open label, active-
control study. The active-control arm therapy was neo-
natal opium solution. Although designed as a safety
study, the mean length of treatment for the buprenor-
phine group (22 vs. 32 days) and of hospital stay (27 vs.
38 days) was clinically but not statistically significant
[52]. In the second study of a revised dosing schedule
based on these safety data, statistically significant differ-
ences were seen in length of treatment and length of
stay (Table 3) [53].
Three studies examined the efficacy of an adjunct
medication versus first-line therapy alone to reduce
treatment duration and hospital stay for infants with
NAS, all of which were RCTs (Table 3). Adjunct medica-
tion with clonidine (two studies) and phenobarbital (one
study) was started at the same time as the first-line opi-
oid in all three studies. These studies showed that ad-
junct therapy could reduce the duration of treatment
with first-line therapy at clinically important levels,
resulting in an average cost savings of ~ $36,000, but that
the duration of phenobarbital treatment after discharge
could be long, with a range of 2–9 months. Finally, when
clonidine was compared to phenobarbital as an adjunct
medication, infants treated with phenobarbital had a
shorter duration of treatment [54-56].
Discussion
The initial development of NAS scoring systems in the
1970s was a crucial turning point in the care of infants
exposed to opioids when pediatricians recognized the
need for a consistent way to assess exposure. However,
Table 2 Studies of the nonpharmacologic management of neonatal management syndrome
Reference Study design Study objective Index vs. reference group(s) Assessment tool Results
Abdel-Latif,
2006 [38]




with NAS (n = 85)
Finnegan Score Rx for NAS: OR = 0.36
(CI 0.18–0.71)*
Formula-fed infants
with NAS (n = 105)
Mean LOS: 14.7 (SD 14.9)
vs. 19.1 (SD 15.0) days*
Dryden,
2009 [42]




with NAS (n = 99)
Modified Lipsitz Rx for NAS: OR =
0.55 (CI 0.34–0.88)*
Formula-fed infants
with NAS (n = 351)
McQueen,
2011 [39]




with NAS (n = 8)
Modified Finnegan Mean # of NAS scores:
25.0 (SD 23.5) vs. 56.2
(SD 39.1) vs. 95.6 (SD 34.6)*
Combination-fed infants
with NAS (n = 11)
Mean NAS score 4.9 (SD 2.9)
vs. 6.5 (SD 3.7) vs. 6.9 (SD 4.2)*
Formula-fed infants
with NAS (n = 9)
Pritham,
2012 [43]




NAS (n = 14)
Not specified Mean LOS: −3.3 (SE 1.7) days
Infants combination-fed
with NAS (n = 22)
Formula-fed infants
with NAS (n = 96)
O’Connor,
2013 [40]




with NAS (n = 65)
Modified Finnegan Mean NAS score: 8.83
(SD 3.56) vs. 9.65 (SD 2.58)
Formula-fed infants
with NAS (n = 20)
Rx for NAS: 23.1% vs. 30.0%
Wachman,
2013 [9]




with NAS (n = 38)
Modified Finnegan Rx for NAS: 50% vs. 77%*
Formula-fed infants
with NAS (n = 48)
Mean LOS: 15.8 (CI 11.5–20.1)
vs. 27.4 (CI 22.5–32.3) days*
Welle-Strand,
2013 [41]




with NAS (n = 95)
Modified Finnegan Rx for NAS: 53% vs. 80%*
outcomes Formula-fed infants
with NAS (n = 29)
Mean length of Rx:
28.6 (SD 19.1) vs.
46.7 (SD 26.3) days*
Hunseler,
2013 [44]
Retrospective Cohort To describe association
between rooming-in
and NAS outcomes
NAS infants exposed to
rooming-in (n = 24)
Finnegan Finnegan Score > 12:
6.3% vs. 6.4%
Control NAS
infants (n = 53)
Rx for NAS: 79.2% vs. 88.7%
Mean length of Rx:
27 vs. 32.5 days
Mean LOS: 38 vs. 41.5 days
Abrahams,
2007 [45]





rooming-in (n = 32)
Modified Finnegan Mean length of Rx: 5.9 vs.
18.6 days*; 5.9 vs. 18.6 days*
Control infants
with NAS (n = 38)
(historical comparison)
Mean LOS: 11.8 vs. 23.5
days; 11.8 vs. 25.9 days*
Control infants
with NAS (n = 36)
(from another institution)
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To determine the association
between infants sleeping
in a rocking bed vs. controls
with NAS outcomes
Infants with NAS exposed
to rocking bed (n = 7)
Finnegan Mean NAS score on day
7 of intervention: 10.2
(SD 2.1) vs. 8.0 (SD 1.8)
Control infants




of Rx with Matched
Controls
To determine the association
between infants sleeping
in a waterbed vs. controls
and NAS outcomes
Infants with NAS exposed
to a waterbed (n = 15)
Finnegan Maximum NAS score:
6.2 (SD 0.7) vs. 6.4 (SD 1.0)
Control infants
with NAS (n = 15)
Mean LOS: 10.5 (SD 1.2)






To determine the association
between sleeping position
with NAS outcomes
Infants with NAS placed in
prone position (n = 25)
Finnegan Maximum NAS score:
10.52 (SD 2.08) vs. 13.17
(SD 2.03)*
Infants with NAS
placed in the supine
position (n = 23)
Mean NAS score: 5.11
(SD 0.64) vs. 7.60 (SD 0.70)*
Filippelli,
2012 [49]
Case Series To describe the possible effects
of NIA on infants with NAS
Infants with NAS
exposed to NIA (n = 54)
Not applicable Chart review revealed
improvements in calming,
sleep, and feeding
Abbreviations: NAS Neonatal Abstinence Syndrome, Rx Treatment, # Number, LOS Length of Hospital Stay, OR Odds ratio, CI 95% confidence interval, SD Standard
deviation, SE Standard error.
*p < 0.05.
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modified and is used differently across institutions. Nur-
series and NICUs have highly variable practices that
range from use of published abstinence tools to incon-
sistent assessment strategies [4,10,57]. As the incidence
and clinical impact of NAS rises, it is critical for infant
care that clinicians employ a common, objective, and
validated tool to guide diagnosis and treatment of NAS.
In other disease states and syndromes, there are agreed-
upon criteria for diagnosis, and the same standards should
be expected for infants with NAS. Without consistency, it
is impossible to assure quality care. The American Acad-
emy of Pediatrics (AAP) recommends use of a standard-
ized tool such as the gold-standard Finnegan abstinence
assessment for evaluation of NAS [4]. They also recom-
mend an inter-observer reliability program offered for
quality improvement efforts. We recommend the use of
such established educational programs utilizing the FS
manual and DVD (such as that offered by Neo Advances)
to standardize scoring among care providers [58]. This
standardization may lead to a decrease in the extent of
pharmacotherapy used and length of hospitalization
needed for affected infants across the United States.
The Lipsitz tool includes similar signs and symptoms,
but is shorter. Despite the widespread use of these vari-
ous tools, validation and inter-observer reliability data is
lacking. Infants are typically scored using various tools
every 3–4 hours starting shortly after birth and are
monitored for 5–10 days for signs of opioid withdrawal
in the hospital. If infants meet a threshold score on the
assessment tool, such as > 8 on the commonly used FS,
they are typically started on pharmacologic therapy.Morphine and methadone remain the two most com-
monly used first-line medications, with lack of evidence
for which agent is superior. Morphine is given orally
and is typically dosed every 3–4 hours at 0.3–1.0 mg/kg/
day, titrated to effect, and then weaned every 24–48 hours.
Methadone is also given orally and dosed every 4–12
hours, titrated in a similar range of 0.3 – 1.0mg/kg/day,
and then weaned over time. Methadone-weaning protocols
vary greatly, with some institutions weaning this medica-
tion as an outpatient treatment over a longer period of
time. Administration of second-line agents for more severe
withdrawal consists of a variety of agents including pheno-
barbital, clonidine, and clonazepam [4,5,24].
Although limited, the available evidence suggests that
nonpharmacologic interventions may provide some bene-
fit for infants with NAS by decreasing clinical symptoms
and the need for pharmacologic therapy. Standard practice
for treating drug-exposed infants includes limiting expos-
ure to sounds and lights and promoting clustering of care,
swaddling, and holding, as well as breastfeeding for eli-
gible patients. Evidence is growing that breastfeeding is
beneficial for this population [9,38-43]. Breastfeeding is
recommended by AAP for the first 6 months of life for
all infants without contraindications. Although specific
criteria vary by institution, the general recommendation
is that infants exposed to opioids in utero should be
breastfed if the mother is enrolled in a substance abuse
program. Even in those mothers who are eligible, there
have generally been low breastfeeding rates in this
population, likely secondary to inherent feeding difficul-
ties in these infants [12,34,35,59]. Other interventions
such as rooming-in may also be beneficial and cost
Table 3 Studies of pharmacologic treatment for neonatal abstinence syndrome





Jackson, 2004 [50] Double-blind RCT Efficacy of opioid vs. phenobarbitone
as first-line therapy
Morphine (n = 41)
Phenobarbitone (n = 34)
Lipsitz Mean length of Rx 8 vs. 12 days* (unadjusted)
Langenfeld, 2005 [51] Randomized Trial,
Blinding Not Specified
Compare tincture of opium
to oral morphine
Morphine (n = 17) Finnegan Mean length of Rx 29.8 vs. 26.9 days
Tincture of Opium
(n = 16)
Mean LOS 37.5 vs. 32.4 days
Kraft, 2008 [52] Phase I, Randomized,
Open Label, Active Control
Feasibility and safety of
buprenorphine in Rx of NAS
Buprenorphine (n = 13) Modified Finnegan Mean length of Rx 22 (SD 12) vs. 32 (SD 16) days
Neonatal opium
solution (n = 13)
Mean LOS 27 (SD 11) vs. 38 (SD 13) days
Kraft, 2011 [53] Phase I, Randomized,
Open Label, Active Control
Feasibility and safety of buprenorphine Buprenorphine (n = 12) Modified Finnegan Mean length of Rx 23 vs. 38 days*
Morphine (n = 12) Mean LOS 23 vs. 42 days
Coyle, 2002 [54] Partially Randomized,
Controlled Trial
Assess whether Rx with




Finnegan Finnegan Scores Infants in placebo group,
spent more time with FS > 7 *
DTO + placebo (n = 10) Infants in phenobarbital group
spent more time with FS < 5*
Mean LOS Mean: 38 vs. 79 days*
Agthe, 2009 [55] Randomized, Double-
Blinded Controlled Trial
To assess use of clonidine as an
adjunct therapy to opioids to
manage NAS
Clonidine (n = 40) Modified Finnegan Mean length of Rx 11 (95% CI 8–15) vs.
15 (95% CI 12–17) days
Placebo (n = 40)
Surran, 2013 [56] Randomized, Nonblinded
Controlled Trial
Clonidine versus phenobarbital
to reduce # days of Rx with
morphine sulfate
Phenobarbital (n = 34) Modified Finnegan Length of Rx with
morphine sulfate
B = −4.6 days (95% CI 0.3–8.9)*
Clonidine (n = 32)
Abbreviations: NAS Neonatal Abstinence Syndrome, Rx Treatment, # Number, LOS Length of Hospital Stay, DTO Diluted Tincture of Opium.
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http://www.ascpjournal.org/content/9/1/19effective. Both breastfeeding and rooming-in can provide
opportunities for bonding and also normalize the postpar-
tum process for women who may feel vulnerable and stig-
matized because of their opioid use history. As it would
be difficult to conduct randomized trials of interventions
that are current standard of care, further studies should
focus on how to increase the rates of breastfeeding and
rooming-in. The limited available evidence about NIA
suggests it may be beneficial, but more studies are needed
and a randomized controlled design would be feasible.
There are currently no FDA-approved medications for
NAS, and the data supporting one specific treatment is
lacking. The studies examining pharmacotherapy efficacy
are small; they have used different assessment tool and
protocols to escalate and wean medications and were in-
consistently adjusted for covariates such as maternal
smoking history, exposure to other substances, and feed-
ing methods and are therefore very difficult to compare.
There is a need for high-quality RCTs to determine best
practices and to establish safety and efficacy. The AAP
recommends use of oral morphine solution or methadone
when indicated, but notes that the best options for adjunct
therapy are not known as well as the best treatment op-
tions for infants with polyexposure [4]. Although prelim-
inary, the use of buprenorphine to treat NAS shows
promise, but further research should be done that includes
feasibility testing because administering it sublingually
might present some administrative challenges.
The number of infants exposed to opioids in utero
and developing NAS has dramatically risen in the last 10
years; based on current trends, the incidence will in-
crease over the next decade. In addition, as knowledge
about predicting NAS severity based on genetics and
prenatal treatment of the mother expand, rigorous high-
quality research should follow. As illustrated by the evi-
dence for nonpharmacologic interventions, it is crucial
to consider the infant with NAS as part of an infant–
mother dyad because treatment of the infant does not
occur in isolation from the mother. Creating a more se-
cure, compassionate, and comfortable environment for
the dyad will likely optimize outcomes for both mother
and infant. Currently, the care for those infants, includ-
ing assessment and management, varies widely across
the country, and existing guidelines are based on min-
imal data. We recommend that nurseries adopt standard
protocols that include use of published assessment tools
and accepted NAS treatment such as morphine and
methadone, as well as the training of all staff involved in
infant care. Further research is urgently needed to assure
the best care for infants with NAS, some of which
should focus on the variations of NAS expression.Competing interests
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